Acute Myocardial Infarction (AMI)Phase 4MUST ⅡNCT07153744
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
A Phase 4 study testing Aspirin and Shexiang Baoxin Pill in people with Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI), run by Shanghai Hutchison Pharmaceuticals Limited at 1 site in China.
Trial summary
This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
- What is being tested?
- Aspirin and Shexiang Baoxin Pill
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9,588 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2025to 31 Dec 2029
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 years or older, regardless of gender
- In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes
- Presenting for treatment within <24 hours of symptom onset and scheduled to undergo PCI
- The patient or their guardian has signed the informed consent form
Who cannot join
- Having contraindications to PCI treatment
- Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration
- Being pregnant, planning to become pregnant, or breastfeeding women
- Having participated in other clinical studies within 3 months
- Being deemed unsuitable for inclusion in this study by the researcher
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Zhongshan Hospital, Fudan University
Shanghai, 200032
Hongbo Yang, doctorate in medicine, +86 13585890793, yang.hongbo@zs-hospital.sh.cn
Jing min Zhou, doctorate in medicine
About this study
Official title: Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study
This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.
- Being tested
- Aspirin, Shexiang Baoxin Pill
- Keywords
- Acute Myocardial Infarction, AMI, Percutaneous Coronary Intervention, PCI, Shexiang Baoxin Pill, MUSKARDIA, Shexiang Baoxin Pill(MUSKARDIA), SBP
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirinDrug
Also called standard guideline-directed therapy, ABCDE, Antiplatelet, Beta-blocker
Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
Shexiang Baoxin PillDrug
Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
| Study group | Role | What they receive |
|---|---|---|
| the Shexiang Baoxin Pill Group | Experimental | Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. Receives: Drug: Shexiang Baoxin Pill |
| the Conventional Treatment Group | Active comparator | Patients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months. Receives: Drug: Aspirin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of major adverse cardiovascular and cerebrovascular events (MACE)
Cumulative incidence of MACE events at 1 year from the start of randomization. MACE events include cardiac death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for angina pectoris, and unplanned revascularization.
Measured: 1 year after PCI
Secondary outcomes (9)
Incidence of non-fatal myocardial infarction
Measured: 1 year after PCI
Incidence of non-fatal stroke
Measured: 1 year after PCI
Rehospitalization rate due to angina pectoris
Measured: 1 year after PCI
Rate of unplanned revascularization
Measured: 1 year after PCI
Cardiac mortality rate
Measured: 1 year after PCI
Rehospitalization rate due to heart failure
Measured: 1 year after PCI
All-cause mortality rate
All-cause mortality rate: including cardiac and non-cardiac deaths
Measured: 1 year after PCI
Seattle Angina Questionnaire score
Measured: 1 year after PCI
EQ-5D-5L scale
Measured: 1 year after PCI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2025
- Study start1 Sep 2025 (estimated)
- Primary completionDec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Stratified block randomization by center was performed using a computer-generated random sequence to allocate patients to the Shexiang Baoxin Pill group and the conventional treatment group at a ratio of 2:1. Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. Patients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months.
- Masking
- None (open label)
- Enrolment
- 9,588 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Shanghai Zhongshan Hospital, Huashan Hospital, Shanghai 10th People's Hospital, Shanghai 6th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai East Hospital, Longhua Hospital, Second Affiliated Hospital of Soochow University, Affiliated Hospital of Jiangsu University, The First Affiliated Hospital with Nanjing Medical University, The First People's Hospital of Lianyungang, Huai'an First People's Hospital, Sir Run Run Shaw Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine, First Affiliated Hospital of Ningbo University, Shandong Provincial Hospital, Qianfoshan Hospital, Weihai Municipal Hospital, Weifang People's Hospital, Rizhao People's Hospital, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Linyi People's Hospital, Xiangya Hospital of Central South University, Second Xiangya Hospital of Central South University, Yueyang Central Hospital, The First Affiliated Hospital of University of South China, The Central Hospital of Shaoyang, The First People's Hospital of Changde City, Wuxi People's Hospital, Jinhua Central Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, ZhuZhou Central Hospital, First People's Hospital of Chenzhou, People's Hospital of Quzhou, Xuzhou New Health Hospital, Taizhou Enze Medical Center Group, Beijing Chao Yang Hospital, Civil Aviation General Hospital, Xuanwu Hospital, Beijing, Beijing Friendship Hospital, Peking University People's Hospital, Beijing Electric Power Hospital, Renmin Hospital of Wuhan University, Wuhan No.1 Hospital, Jingzhou Central Hospital, The First Affiliated Hospital of Dalian Medical University, Ansteel Group General Hospital, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, The First Affiliated Hospital of Zhengzhou University, Huaihe Hospital of Henan University, Zhoukou Central Hospital, The First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Nanyang Medical College, Jiaozuo Second People's Hospital, Anyang Area Hospital of Puyang City, Shijiazhuang People's Hospital, Cangzhou Central Hospital, The First Hospital of Hebei Medical University, Handan Central Hospital, The People's Hospital of Langfang City, Xingtai Central Hospital, North China University of Science and Technology, The First Affiliated Hospital of Anhui Medical University, the First Hospital of Anhui University of Science and Technology, Chaohu Hospital of Anhui Medical University, Tongling People's Hospital, Huang Shan People's Hospital, Huaibei Miners General Hospital, The Second Affiliated Hospital of Fujian Medical University, Changzhi Medical College, Linfen No.4 People's Hospital, Shanxi Cardiovascular Hospital, Dazhou First People's Hospital, The Affiliated Hospital Of Southwest Medical University, The Third Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Yangchun People's Hospital, Shaoguan People's Hospital, Guilin People's Hospital, The First Affiliated Hospital of Nanchang University, Jinan Central Hospital, Jiangxi Provincial People's Hopital, People's Hospital of Chongqing, Ankang Central Hospital, Xiangyang Central Hospital, Tianjin Third Central Hospital, General Hospital of Ningxia Medical University, The Second Affiliated Hospital of Hainan Medical University, Lanzhou University Second Hospital, Jilin Provincial People's Hospital, Inner Mongolia Autonomous Region People's Hospital, Yan'an Affiliated Hospital of Kunming Medical University, The People's Hospital of Jizhou District, Tianjin, The Southwest Hospital of Army Medical University, The First People's Hospital of Nanning, The People' s Hospital of Jiangmen, The second People's Hospital of Guiyang, The Third People's Hospital of Chengdu, The Tirst People's Hospital of Mianyang, First Affiliated Hospital of Fujian Medical University, The First People's Hospital of Chu Zhou, Xuancheng People's Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07153744
- Sponsor's protocol ID
- HMPE202501
- Acronym
- MUST Ⅱ
- Status last verified
- Aug 2025
- First submitted
- 26 Aug 2025
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study
- ClinicalTrials.gov ID
- NCT07153744
- Acronym / sponsor ID
- MUST Ⅱ / HMPE202501
- Keywords
- Acute Myocardial Infarction, AMI, Percutaneous Coronary Intervention, PCI, Shexiang Baoxin Pill, MUSKARDIA, Shexiang Baoxin Pill(MUSKARDIA), SBP
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 9,588 participants (estimated)
- Lead sponsor
- Shanghai Hutchison Pharmaceuticals LimitedIndustry (pharma, biotech, devices)
- Collaborators
- Shanghai Zhongshan Hospital, Huashan Hospital, Shanghai 10th People's Hospital, Shanghai 6th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai East Hospital, Longhua Hospital, Second Affiliated Hospital of Soochow University, Affiliated Hospital of Jiangsu University, The First Affiliated Hospital with Nanjing Medical University, The First People's Hospital of Lianyungang, Huai'an First People's Hospital, Sir Run Run Shaw Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine, First Affiliated Hospital of Ningbo University, Shandong Provincial Hospital, Qianfoshan Hospital, Weihai Municipal Hospital, Weifang People's Hospital, Rizhao People's Hospital, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Linyi People's Hospital, Xiangya Hospital of Central South University, Second Xiangya Hospital of Central South University, Yueyang Central Hospital, The First Affiliated Hospital of University of South China, The Central Hospital of Shaoyang, The First People's Hospital of Changde City, Wuxi People's Hospital, Jinhua Central Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, ZhuZhou Central Hospital, First People's Hospital of Chenzhou, People's Hospital of Quzhou, Xuzhou New Health Hospital, Taizhou Enze Medical Center Group, Beijing Chao Yang Hospital, Civil Aviation General Hospital, Xuanwu Hospital, Beijing, Beijing Friendship Hospital, Peking University People's Hospital, Beijing Electric Power Hospital, Renmin Hospital of Wuhan University, Wuhan No.1 Hospital, Jingzhou Central Hospital, The First Affiliated Hospital of Dalian Medical University, Ansteel Group General Hospital, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, The First Affiliated Hospital of Zhengzhou University, Huaihe Hospital of Henan University, Zhoukou Central Hospital, The First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Nanyang Medical College, Jiaozuo Second People's Hospital, Anyang Area Hospital of Puyang City, Shijiazhuang People's Hospital, Cangzhou Central Hospital, The First Hospital of Hebei Medical University, Handan Central Hospital, The People's Hospital of Langfang City, Xingtai Central Hospital, North China University of Science and Technology, The First Affiliated Hospital of Anhui Medical University, the First Hospital of Anhui University of Science and Technology, Chaohu Hospital of Anhui Medical University, Tongling People's Hospital, Huang Shan People's Hospital, Huaibei Miners General Hospital, The Second Affiliated Hospital of Fujian Medical University, Changzhi Medical College, Linfen No.4 People's Hospital, Shanxi Cardiovascular Hospital, Dazhou First People's Hospital, The Affiliated Hospital Of Southwest Medical University, The Third Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Yangchun People's Hospital, Shaoguan People's Hospital, Guilin People's Hospital, The First Affiliated Hospital of Nanchang University, Jinan Central Hospital, Jiangxi Provincial People's Hopital, People's Hospital of Chongqing, Ankang Central Hospital, Xiangyang Central Hospital, Tianjin Third Central Hospital, General Hospital of Ningxia Medical University, The Second Affiliated Hospital of Hainan Medical University, Lanzhou University Second Hospital, Jilin Provincial People's Hospital, Inner Mongolia Autonomous Region People's Hospital, Yan'an Affiliated Hospital of Kunming Medical University, The People's Hospital of Jizhou District, Tianjin, The Southwest Hospital of Army Medical University, The First People's Hospital of Nanning, The People' s Hospital of Jiangmen, The second People's Hospital of Guiyang, The Third People's Hospital of Chengdu, The Tirst People's Hospital of Mianyang, First Affiliated Hospital of Fujian Medical University, The First People's Hospital of Chu Zhou, Xuancheng People's Hospital
- Study start
- 1 Sep 2025 (estimated)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 4 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Stratified block randomization by center was performed using a computer-generated random sequence to allocate patients to the Shexiang Baoxin Pill group and the conventional treatment group at a ratio of 2:1. Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. Patients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months.
| Arm | Type | Receives |
|---|---|---|
| the Shexiang Baoxin Pill Group | Experimental | Drug: Shexiang Baoxin PillPatients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. |
| the Conventional Treatment Group | Active comparator | Drug: AspirinPatients in the conventional treatment group will receive standard treatment in accordance with guidelines and consensuses after surgery, and this will last for 12 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Aged 18 years or older, regardless of gender
- In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes
- Presenting for treatment within <24 hours of symptom onset and scheduled to undergo PCI
- The patient or their guardian has signed the informed consent form
Key exclusion criteria (5 listed)
- Having contraindications to PCI treatment
- Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration
- Being pregnant, planning to become pregnant, or breastfeeding women
- Having participated in other clinical studies within 3 months
- Being deemed unsuitable for inclusion in this study by the researcher
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AspirinAlso: standard guideline-directed therapy, ABCDE, Antiplatelet, Beta-blockerPatients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. | Drug | the Conventional Treatment Group |
| Shexiang Baoxin PillPatients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy. | Drug | the Shexiang Baoxin Pill Group |
Primary outcome
Incidence of major adverse cardiovascular and cerebrovascular events (MACE)
Time frame: 1 year after PCI
Cumulative incidence of MACE events at 1 year from the start of randomization. MACE events include cardiac death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for angina pectoris, and unplanned revascularization.
9 secondary outcomes
Incidence of non-fatal myocardial infarction
Time frame: 1 year after PCI
Incidence of non-fatal stroke
Time frame: 1 year after PCI
Rehospitalization rate due to angina pectoris
Time frame: 1 year after PCI
Rate of unplanned revascularization
Time frame: 1 year after PCI
Cardiac mortality rate
Time frame: 1 year after PCI
Rehospitalization rate due to heart failure
Time frame: 1 year after PCI
All-cause mortality rate
Time frame: 1 year after PCI
Seattle Angina Questionnaire score
Time frame: 1 year after PCI
EQ-5D-5L scale
Time frame: 1 year after PCI
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- National Universal Health Security Information Platform - Medical Research Registration and Filing Information SystemLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Aspirin and Shexiang Baoxin Pill in people with Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI), run by Shanghai Hutchison Pharmaceuticals Limited at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fang Wang, of Medicine (M.Med.) (+86 13818403261, wangfang@shpl.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of major adverse cardiovascular and cerebrovascular events (MACE) (time frame: 1 year after PCI). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.